Back to articles
Comparative guide · 7 min read

EPA vs DHA — when each omega-3 actually outperforms the other

Updated 2026-05-14 · Reviewed by SupplementScore editors · No sponsorships

The two long-chain marine omega-3s do different things and the ratio in your fish-oil capsule matters. EPA dominates the depression and inflammation case; DHA dominates the pregnancy, infant neurodevelopment, and dry-eye case. The cardiovascular and triglyceride evidence largely runs on EPA (notably the REDUCE-IT trial of icosapent ethyl).

Quick verdict

GoalBetter choiceWhy
Major depression / adjunctive in mood disordersEPA-dominant (≥60% EPA, 1–2 g EPA/day)Meta-analyses (Sublette 2011, Mocking 2016) consistently favor EPA-predominant formulations for depression.
Hypertriglyceridemia (very high triglycerides)EPA (icosapent ethyl, prescription)REDUCE-IT showed cardiovascular benefit with 4 g/day icosapent ethyl in statin-treated patients with elevated TGs.
Pregnancy / fetal neurodevelopmentDHA (200–300 mg/day minimum)DHA is structural in developing brain and retina; most pregnancy guidelines specify a DHA minimum.
Cognitive aging / mild cognitive impairmentDHA-leaning (mixed evidence)DHA is the structural omega-3 in brain phospholipids; trials have been mixed but lean DHA when positive.
Dry eye diseaseSlight DHA edge; combinedRe-esterified TG form combinations are typical; DHA contribution to meibomian secretions.
Generic cardiovascular benefit / "fish oil for the heart"Combined EPA+DHA, but modest expectationsVITAL and ASCEND showed minimal benefit at 1 g/day; high-dose icosapent ethyl is the standout.

How they actually work

EPA — anti-inflammatory eicosanoid precursor

Eicosapentaenoic acid (20:5n-3) is the precursor of series-3 prostaglandins, series-5 leukotrienes, and the E-series resolvins. These mediators are less inflammatory than the arachidonic-acid-derived series-2 and -4 counterparts. EPA competes with arachidonic acid for the same enzymatic pathways (COX, LOX), shifting eicosanoid balance toward less inflammation. It is heavily β-oxidised for energy and only a small fraction enters tissue phospholipids — which is why EPA-predominant supplements raise serum EPA easily but raise tissue DHA more slowly.

DHA — structural neural and retinal phospholipid

Docosahexaenoic acid (22:6n-3) is the predominant omega-3 in brain gray matter, retinal photoreceptor membranes, and synaptic membranes. It is structural rather than primarily signaling — though it is also the precursor of the D-series resolvins and neuroprotectins. DHA is retained tissue-side more efficiently than EPA. Pregnancy and lactation deplete maternal DHA stores; the DHA in breastmilk is highly dependent on maternal intake.

The depression case — EPA wins consistently

Meta-analyses of omega-3 in major depression find consistent superiority of EPA-predominant formulations over DHA-predominant ones. The most-cited threshold is at least 60% EPA in the product, at total doses of 1–2 g EPA/day, for 8+ weeks. The Mocking 2016 meta-analysis is the cleanest summary. DHA-predominant or balanced products do not show the same effect. This is one of the few cases where the EPA/DHA ratio is clinically meaningful and worth checking on the label.

The triglyceride and cardiovascular case

The REDUCE-IT trial (2019, NEJM) showed 4 g/day icosapent ethyl (purified EPA ethyl ester) reduced major cardiovascular events by 25% in statin-treated patients with elevated triglycerides. Conversely, the STRENGTH trial of an EPA+DHA carboxylic acid formulation at the same total dose was negative — suggesting the EPA-specific mechanism, the mineral-oil placebo question, or some interaction. The IFC and ESC guidelines now recommend icosapent ethyl in selected high-risk patients with elevated triglycerides. Plain 1 g/day fish oil over-the-counter does not show the same cardiovascular benefit (VITAL, ASCEND).

The pregnancy case — DHA wins

DHA accrual in fetal brain and retina is highest in the third trimester and continues through the first 18 months postnatally. Pregnancy guidelines specify a DHA minimum (typically 200–300 mg/day), met by prenatal vitamins with DHA or a separate DHA capsule. Algal DHA is acceptable for vegetarians/vegans. EPA in pregnancy is fine but not the structural priority.

Cognitive aging — mostly DHA-leaning, mostly disappointing

Trials of DHA-predominant omega-3 in mild cognitive impairment and early Alzheimer's are mixed; the larger trials (MIDAS, Yurko-Mauro) showed modest gains in memory measures in healthy older adults but didn't dramatically alter dementia trajectories. The case for high-DHA "brain" formulations in established cognitive decline is overstated by marketing.

Practical rule. For depression / mood: EPA-predominant (e.g., 1,000 mg EPA + 250 mg DHA per day). For triglycerides and high-CV-risk patients: prescription icosapent ethyl (Vascepa) at 4 g/day. For pregnancy: prenatal with at least 200–300 mg DHA, or a separate DHA capsule. For generic "support" use in healthy adults: a combined EPA/DHA 1–1.5 g/day is reasonable but don't expect cardiovascular protection at this dose.

Dose, form, and timing

Look at the EPA and DHA mg per serving, not total "fish oil mg." A "1000 mg fish oil" capsule may contain 180 mg EPA + 120 mg DHA. For mood: aim for ≥1 g EPA/day, from an EPA-predominant product. For pregnancy: aim for ≥200 mg DHA/day. For triglyceride lowering at a meaningful level: 2–4 g total EPA+DHA, or icosapent ethyl by prescription.

The re-esterified triglyceride (rTG) and the icosapent-ethyl (EE) forms differ in absorption. Take with a fat-containing meal — improves absorption substantially.

Safety

Both forms are well-tolerated. Fish burps and reflux are the common complaints; enteric-coated or freezer-stored capsules help. Bleeding risk is modest and mostly relevant at high doses combined with anticoagulants — the ASCEND and REDUCE-IT trials showed small increases in nuisance bleeding without major bleeding signals. Atrial fibrillation signal was raised by the REDUCE-IT and STRENGTH analyses at higher doses; clinically modest but worth knowing.

What we'd actually buy

For most adults: a combined EPA/DHA fish-oil product with around 700 mg EPA + 300 mg DHA per day, or algal omega-3 at equivalent doses for vegetarians/vegans. For users with mood-disorder use: an EPA-predominant product hitting 1 g EPA/day. For pregnancy: prenatal with ≥250 mg DHA or a separate algal DHA. For high CV risk with elevated triglycerides: ask your prescriber about icosapent ethyl.

Sources

Read more: